title: Medical therapy for uveal effusion syndrome.
abstract: OBJECTIVE
  To report a case series of three patients with bilateral uveal effusion syndrome (UES), treated conservatively with oral carbonic anhydrase inhibitors and topical prostaglandin analogues (PAs).
  
  
  METHODS
  Three patients with bilateral UES were treated with the same initial therapy. Topical PA latanoprost 0.005% and acetazolamide 250 mg were administered in order to reduce intraocular pressure, improve uveoscleral outflow, and facilitate resolution of uveal effusion.
  
  
  RESULTS
  The chorioretinal detachment resolved within 3 months in two reported patients while the third one underwent surgery on his left eye. After clinical improvement, further oral therapy with acetazolamide was stopped, while topical prostaglandins were continued for at least the next 3 months. All patients were free from recurrence during the follow-up period.
  
  
  CONCLUSIONS
  Although the usually recommended UES therapy is partial or full-thickness sclerectomy, our case series showed apparent resolution of chorioretinal detachment in two patients on medical therapy alone. Conservative therapy may be the first step before the standard recommended surgical approach, but further studies are needed to verify the effectiveness of reported therapy.
authors.affiliation: University Clinical Centre 'Sestre milosrdnice', University Department of Ophthalmology, Zagreb, Croatia.
authors.forename: B
authors.initials: B
authors.lastname: Andrijević Derk
authors.affiliation: University Clinical Centre 'Sestre milosrdnice', University Department of Ophthalmology, Zagreb, Croatia.
authors.forename: G
authors.initials: G
authors.lastname: Benčić
authors.affiliation: Department of Ophthalmology, General Hospital, Vinkovci, Croatia.
authors.forename: V
authors.initials: V
authors.lastname: Corluka
authors.affiliation: University Clinical Centre 'Sestre milosrdnice', University Department of Ophthalmology, Zagreb, Croatia.
authors.forename: M
authors.initials: M
authors.lastname: Zorić Geber
authors.affiliation: University Clinical Centre 'Sestre milosrdnice', University Department of Ophthalmology, Zagreb, Croatia.
authors.forename: Z
authors.initials: Z
authors.lastname: Vatavuk
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use*; D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D015862:Choroid Diseases / Q000188:drug therapy* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007429:Intraocular Pressure; D000077338:Latanoprost; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D012163:Retinal Detachment / Q000188:drug therapy* / Q000473:pathology; D014603:Uveal Diseases / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000959:Antihypertensive Agents; D002257:Carbonic Anhydrase Inhibitors; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D000086:Acetazolamide